AbbVie beat quarterly earnings expectations as its Botox franchise showed the first convincing signs of revival after years of softness.
Competitors have crowded the neurotoxin space with newer formulations, but Botox’s brand recognition continues to anchor its premium pricing.
AbbVie’s medical aesthetics division remains a small slice of the pharma giant, but it is the part of the business most exposed to consumer sentiment.
The company credited a return to in-office treatments, renewed consumer interest in preventative aesthetics, and a marketing push that repositioned the brand beyond its clinical origins.
The results offer a broader read on the beauty industry: procedures are holding up even as product spending softens, a divergence that reshapes how beauty conglomerates allocate investment.
With the aesthetic cycle turning, the next earnings report will show whether this quarter was a genuine inflection or a temporary bounce.
